Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Assets (2017 - 2025)

Historic Current Assets for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $586.4 million.

  • Protagonist Therapeutics' Current Assets rose 2299.96% to $586.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $586.4 million, marking a year-over-year increase of 2299.96%. This contributed to the annual value of $591.6 million for FY2024, which is 6638.9% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Current Assets stood at $586.4 million, which was up 2299.96% from $602.5 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Current Assets registered a high of $627.6 million during Q1 2024, and its lowest value of $235.7 million during Q1 2023.
  • In the last 5 years, Protagonist Therapeutics' Current Assets had a median value of $341.5 million in 2022 and averaged $409.8 million.
  • In the last 5 years, Protagonist Therapeutics' Current Assets tumbled by 3097.49% in 2023 and then skyrocketed by 16621.01% in 2024.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Current Assets stood at $340.7 million in 2021, then decreased by 28.66% to $243.1 million in 2022, then surged by 46.28% to $355.6 million in 2023, then soared by 66.39% to $591.6 million in 2024, then fell by 0.88% to $586.4 million in 2025.
  • Its Current Assets was $586.4 million in Q3 2025, compared to $602.5 million in Q2 2025 and $605.9 million in Q1 2025.